Delivery Order SPE2DB25D3012-SPE2DB25FWXRU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $47,923.50 to AmerisourceBergen Drug Corp for the supply of FORTEO (560 mcg/2.24 mL pen injection), a pharmaceutical treatment for osteoporosis. The contract, awarded on April 21, 2025, with an ultimate completion date of April 22, 2025, was issued without a set-aside designation under a firm fixed price arrangement. Performance of this delivery order will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,057.77 to AmerisourceBergen Drug Corp for the supply of FORTEO 560 MCG/2.24 ML pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $6,492.02 delivery order to AmerisourceBergen Drug Corp for FORTEO (forteoide) 560 mcg/2.24 mL pen injections on September 8, 2025, with completion scheduled for September 9, 2025. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order to be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. FORTEO is a prescription injectable medication commonly used in the treatment of osteoporosis...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,220.43 for FORTEO 560 mcg/2.24 mL pen injections on June 3, 2025, with completion targeted for June 4, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio. The product will be performed at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $12,869.67 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections), a brand-name pharmaceutical product used in osteoporosis treatment. The contract is a firm fixed-price delivery order with an ultimate completion date of May 19, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a $2,601.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for FORTEO (Fortified Growth Factor) 560 MCG/2.24 ML pen injections on June 18, 2025, with completion targeted for June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement to support federal medical supply needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,601.43 to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections on July 21, 2025, with completion targeted for July 22, 2025. This firm fixed price contract, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $14,640.18 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections) on April 24, 2025, with completion scheduled for April 25, 2025. This competitive award utilizes firm fixed pricing and is performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,764.33 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of FORTEO 560 MCG/2.24 ML pen injections. This is a firm fixed-price delivery order with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $55,993.09 to AmerisourceBergen Drug Corp for FORTEO (forteoide) 560 micrograms per 2.24 milliliters pen injections on August 19, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued under...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWXRUDelivery Order
The Defense Logistics Agency has awarded a $15,608.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of FORTEO (forteoide) 560 mcg/2.24 mL pen injections. The contract, awarded on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. FORTEO is a prescription injectable medication commonly used in the treatment of osteoporosis and bone-related conditions. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain, fulfilling the Department of Defense's requirement for specialized medications to support military healthcare programs. The company's extensive portfolio of federal contracts demonstrates its capability to meet competitive procurement standards while delivering a diverse range of therapeutic products, from specialty medications to generic pharmaceuticals, across multiple therapeutic domains in support of military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 5/30/25 |